Antithrombotic Treatment after Percutaneous Coronary or Aortic Valve Interventions

Dear Colleagues,

Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 receptor inhibitors is the cornerstone of medical treatment after percutaneous coronary intervention (PCI) and stent implantation, aiming to decrease the risk of coronary stent-related and non-related thrombotic events. On the other hand, this strategy also increases the risk of bleeding over time. Of note, coronary thrombotic events and bleeding are associated with mortality risks of comparable magnitude after PCI, findings that should be taken into account in the risk/benefit calculations for extension versus discontinuation of DAPT. However, despite a large number of studies, the duration of DAPT remain unclear, in particular for patients at high risks, such as patients undergoing non-cardiac surgery, with history of malignancy or with recurrent coronary thrombotic events. Similarly, antithrombotic treatment is of paramount importance in patients undergoing transcatheter aortic valve replacement (TAVR) because of the increasing risk of valve thrombosis and thromboembolic events after procedure. The introduction in clinical practice of new generation devices and antithrombotic agents offer a broader spectrum of therapeutic options after PCI and TAVR procedures. This Special Issue will summarize new recommendations on optimal DAPT duration and decision-making tools in patients undergoing TAVR or PCI, based on original articles and systematic reviews.

Dr. Sabato Sorrentino
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.